Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 36
Filter
Add more filters










Publication year range
1.
J Equine Vet Sci ; 136: 105063, 2024 May.
Article in English | MEDLINE | ID: mdl-38608970

ABSTRACT

A 17-year-old mare presenting with acute fever, weakness and bladder dysfunction was diagnosed with equine herpesvirus myeloencephalopathy (EHM). The mare become transiently recumbent, underwent parenteral fluid therapy, plasma infusion, steroidal/nonsteroidal anti-inflammatory drugs (SAID/NSAIDs) and bladder catheterization. After 10 days the mare was hospitalized. Neurological evaluation revealed ataxia and proprioceptive deficits mainly in the hind limbs. The mare was able to stand but unable to rise from recumbency or walk. Secondary complications included Escherichia coli cystitis, corneal ulcers and pressure sores. A full-body support sling was used for 21 days. Medical treatment included systemic antimicrobials, NSAIDs, gradual discontinuation of SAIDs, parenteral fluid therapy and bladder lavage. The mare tested positive for Varicellovirus equidalpha 1 (EHV-1) DNA in nasal swab and blood samples on day 13 and in urine samples on days 13 and 25 after the onset of fever. Neurological signs improved over a period of 34 days and the mare was discharged with mild hind limb weakness/ataxia. Secondary complications resolved within 2 weeks. At the eight-month follow-up, marked improvement in locomotory function had been achieved.


Subject(s)
Herpesviridae Infections , Horse Diseases , Horses , Animals , Female , Horse Diseases/virology , Horse Diseases/drug therapy , Herpesviridae Infections/drug therapy , Herpesviridae Infections/veterinary , Herpesviridae Infections/complications , Herpesvirus 1, Equid/drug effects
2.
J Vet Intern Med ; 38(3): 1892-1905, 2024.
Article in English | MEDLINE | ID: mdl-38380685

ABSTRACT

BACKGROUND: Equine herpes virus type 1 (EHV-1) infection in horses is associated with upper respiratory disease, neurological disease, abortions, and neonatal death. REVIEW QUESTION: Does pharmacological therapy decrease either the incidence or severity of disease or infection caused by EHV-1 in domesticated horses? METHODS: A systematic review was preformed searching AGRICOLA, CAB Abstracts, Cochrane, PubMed, Web of Science, and WHO Global Health Index Medicus Regional Databases to identify articles published before February 15, 2021. Selection criteria were original research reports published in peer reviewed journals, and studies investigating in vivo use of therapeutic agents for prevention or treatment of EHV-1 in horses. Outcomes assessed included measures related to clinical outcomes that reflect symptomatic EHV-1 infection or virus infection. We evaluated risk of bias and performed a GRADE evaluation of the quality of evidence for interventions. RESULTS: A total of 7009 unique studies were identified, of which 9 met the inclusion criteria. Two studies evaluated valacyclovir or small interfering RNAs, and single studies evaluated the use of a Parapoxvirus ovis-based immunomodulator, human alpha interferon, an herbal supplement, a cytosine analog, and heparin. The level of evidence ranged between randomized controlled studies and observational trials. The risk of bias was moderate to high and sample sizes were small. Most studies reported either no benefit or minimal efficacy of the intervention tested. CONCLUSIONS AND CLINICAL IMPORTANCE: Our review indicates minimal or limited benefit either as a prophylactic or post-exposure treatment for any of the studied interventions in the mitigation of EHV-1-associated disease outcome.


Subject(s)
Antiviral Agents , Herpesviridae Infections , Herpesvirus 1, Equid , Horse Diseases , Animals , Horses , Herpesvirus 1, Equid/drug effects , Horse Diseases/drug therapy , Horse Diseases/virology , Herpesviridae Infections/veterinary , Herpesviridae Infections/drug therapy , Antiviral Agents/therapeutic use , Valacyclovir/therapeutic use
3.
Viruses ; 14(1)2022 01 14.
Article in English | MEDLINE | ID: mdl-35062352

ABSTRACT

Respiratory disease in horses is caused by a multifactorial complex of infectious agents and environmental factors. An important pathogen in horses is equine herpesvirus type 1 (EHV-1). During co-evolution with this ancient alphaherpesvirus, the horse's respiratory tract has developed multiple antiviral barriers. However, these barriers can become compromised by environmental threats. Pollens and mycotoxins enhance mucosal susceptibility to EHV-1 by interrupting cell junctions, allowing the virus to reach its basolateral receptor. Whether bacterial toxins also play a role in this impairment has not been studied yet. Here, we evaluated the role of α-hemolysin (Hla) and adenylate cyclase (ACT), toxins derived from the facultative pathogenic bacterium Staphylococcus aureus (S. aureus) and the primary pathogen Bordetella bronchiseptica (B. bronchiseptica), respectively. Equine respiratory mucosal explants were cultured at an air-liquid interface and pretreated with these toxins, prior to EHV-1 inoculation. Morphological analysis of hematoxylin-eosin (HE)-stained sections of the explants revealed a decreased epithelial thickness upon treatment with both toxins. Additionally, the Hla toxin induced detachment of epithelial cells and a partial loss of cilia. These morphological changes were correlated with increased EHV-1 replication in the epithelium, as assessed by immunofluorescent stainings and confocal microscopy. In view of these results, we argue that the ACT and Hla toxins increase the susceptibility of the epithelium to EHV-1 by disrupting the epithelial barrier function. In conclusion, this study is the first to report that bacterial exotoxins increase the horse's sensitivity to EHV-1 infection. Therefore, we propose that horses suffering from infection by S. aureus or B. bronchiseptica may be more susceptible to EHV-1 infection.


Subject(s)
Bacterial Toxins/pharmacology , Bordetella bronchiseptica/metabolism , Herpesviridae Infections/drug therapy , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/drug effects , Horse Diseases/virology , Respiratory Tract Diseases/virology , Staphylococcus aureus/metabolism , Animals , Epithelial Cells/virology , Hemolysin Proteins , Horses , Respiratory Mucosa/drug effects , Respiratory Mucosa/virology , Virus Replication/drug effects
4.
Antiviral Res ; 183: 104931, 2020 11.
Article in English | MEDLINE | ID: mdl-32926887

ABSTRACT

Equid herpesvirus-1 infections cause respiratory, neurological and reproductive syndromes. Despite preventive treatments with vaccines, resurgence of EHV-1 infection still constitutes a major threat to equine industry. However, no antiviral compound is available to treat infected horses. In this study, 2891 compounds were screened against EHV-1 using impedance measurement. 22 compounds have been found to be effective in vitro against EHV-1. Valganciclovir, ganciclovir, decitabine, aphidicolin, idoxuridine and pritelivir (BAY 57-1293) are the most effective compounds identified, and their antiviral potency was further assessed on E. Derm, RK13 and EEK cells and against 3 different field strains of EHV-1 (ORF30 2254 A/G/C). We also provide evidences of synergistic interactions between valganciclovir and decitabine in our in vitro antiviral assay as determined by MacSynergy II, isobologramm and Chou-Talalay methods. Finally, we showed that deoxycytidine reverts the antiviral effect of decitabine, thus supporting some competition at the level of nucleoside phosphorylation by deoxycytidine kinase and/or DNA synthesis. Deoxycitidine analogues, like decitabine, is a family of compounds identified for the first time with promising antiviral efficacy against herpesviruses.


Subject(s)
Antiviral Agents/pharmacology , Decitabine/pharmacology , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/drug effects , Valganciclovir/pharmacology , Animals , Cell Line , Drug Combinations , Drug Discovery/methods , Drug Synergism , Ganciclovir/pharmacology , Herpesviridae Infections/drug therapy , Herpesviridae Infections/virology , High-Throughput Screening Assays/methods , Horses , Rabbits
5.
J Antibiot (Tokyo) ; 72(12): 981-985, 2019 12.
Article in English | MEDLINE | ID: mdl-31534199

ABSTRACT

Feline herpesvirus type 1 (FHV-1) causes a potentially fatal disease in cats. Through the use of virus inhibition and cytotoxicity assays, sinefungin, a nucleoside antibiotic, was assessed for its potential to inhibit the growth of FHV-1. Sinefungin inhibited in vitro growth of FHV-1 most significantly over other animal viruses, such as feline infectious peritonitis virus, equine herpesvirus, pseudorabies virus and feline calicivirus. Our results revealed that sinefungin specifically suppressed the replication of FHV-1 after its adsorption to the host feline kidney cells in a dose-dependent manner without obvious cytotoxicity to the host cells. This antibiotic can potentially offer a highly effective treatment for animals infected with FHV-1, providing alternative medication to currently available antiviral therapies.


Subject(s)
Adenosine/analogs & derivatives , Antiviral Agents/pharmacology , Varicellovirus/drug effects , Adenosine/pharmacology , Adenosine/toxicity , Animals , Antiviral Agents/toxicity , Calicivirus, Feline/drug effects , Cat Diseases/drug therapy , Cats , Cell Line , Coronavirus, Feline/drug effects , Dose-Response Relationship, Drug , Herpesviridae Infections/drug therapy , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/drug effects , Herpesvirus 1, Suid/drug effects , Horses , Kidney/cytology , Kidney/virology , Toxicity Tests
6.
Antiviral Res ; 169: 104546, 2019 09.
Article in English | MEDLINE | ID: mdl-31247247

ABSTRACT

Equine herpesvirus 1 (EHV-1) is the causative agent of a number of equine disease manifestations, including severe disease of the central nervous system, respiratory infections, and abortion storms. Our results showed that intranasal treatment with CpG-B oligodeoxynucleotides (ODN 1826) protected CBA mice from pathogenic EHV-1 RacL11 challenge. The IFN-γ gene and seven interferon-stimulated genes (ISGs) were upregulated 39.4- to 260.3-fold at 8 h postchallenge in the lungs of RacL11-challenged mice that had been treated with CpG-B ODN. Interestingly, IFN-γ gene expression was upregulated by 26-fold upon RacL11 challenge in CpG-B ODN-treated mice lungs as compared to that of CpG-A ODN (ODN 1585)-treated mice lungs; however, the seven ISGs were upregulated by 2.4-5.0-fold, suggesting that IFN-γ is a major factor in the protection of CBA mice from the lethal challenge. Pre-treatment with IFN-γ significantly reduced EHV-1 yield in murine alveolar macrophage MH-S cells, but not in mouse lung epithelial MLE12 cells. These results suggest that CpG-B ODN may be used as a prophylactic agent in horses and provide a basis for more effective treatment of EHV-1 infection.


Subject(s)
Administration, Intranasal/methods , Antiviral Agents/pharmacology , Herpesviridae Infections/drug therapy , Herpesvirus 1, Equid/drug effects , Immunity, Innate/immunology , Oligodeoxyribonucleotides/pharmacology , Protective Agents/pharmacology , Adjuvants, Immunologic , Animals , Cell Line , Female , Herpesviridae Infections/immunology , Herpesviridae Infections/virology , Horses , Interferon-gamma/genetics , Interferon-gamma/metabolism , Lung/virology , Mice , Mice, Inbred CBA , Oligodeoxyribonucleotides/immunology
7.
Virology ; 531: 219-232, 2019 05.
Article in English | MEDLINE | ID: mdl-30928700

ABSTRACT

Equid herpesvirus-1 (EHV-1) outbreaks continue despite widely used vaccination. We demonstrated previously that an ORF1/ORF71 gene deletion mutant of the EHV-1 strain Ab4 (Ab4ΔORF1/71) is less virulent than its parent Ab4 virus. Here, we describe the Ab4 challenge infection evaluating protection induced by the Ab4ΔORF1/71 vaccine candidate. Susceptible control horses developed respiratory disease, fever, nasal shedding, and viremia. Full protection after challenge infection was observed in 5/5 previously Ab4 infected horses and 3/5 Ab4ΔORF1/71 horses. Two Ab4ΔORF1/71 horses developed short-lasting viremia and/or virus shedding. Protective immunity in the respiratory tract was characterized by pre-existing EHV-1-specific IgG4/7 antibodies, the absence of IFN-α secretion and rapidly increasing IgG4/7 upon challenge infection. Pre-existing systemic EHV-1-specific IgG4/7 highly correlated with protection. T-cell immunity was overall low. In conclusion, protective immunity against EHV-1 infection including prevention of viremia was associated with robust systemic and intranasal IgG4/7 antibodies suggesting immediate virus neutralization at the local site.


Subject(s)
Antibodies, Viral/immunology , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/immunology , Herpesvirus Vaccines/administration & dosage , Horse Diseases/prevention & control , Immunoglobulin G/immunology , Viremia/veterinary , Administration, Intranasal , Animals , Female , Herpesviridae Infections/immunology , Herpesviridae Infections/prevention & control , Herpesviridae Infections/virology , Herpesvirus 1, Equid/drug effects , Herpesvirus 1, Equid/genetics , Herpesvirus 1, Equid/physiology , Herpesvirus Vaccines/immunology , Horse Diseases/immunology , Horse Diseases/virology , Horses , Male , Nasal Mucosa/immunology , Nasal Mucosa/virology , Vaccination , Viremia/immunology , Viremia/prevention & control , Viremia/virology , Virus Shedding
8.
Virology ; 526: 105-116, 2019 01 02.
Article in English | MEDLINE | ID: mdl-30388626

ABSTRACT

Equid alpha-herpesviruses (EHV) are responsible for different diseases in equine population. EHV-1 causes respiratory diseases, abortions and nervous disorders, EHV-4 causes respiratory diseases and sporadic abortion, while EHV-3 is responsible of equine coital exanthema. In view of the lack of efficacy of vaccines against EHV-1 and EHV-4 and in the absence of vaccines against EHV-3, the use of antiviral treatment is of great interest. In this study, we documented the interest of the Real-Time Cell Analysis (RTCA) technology to monitor the cytopathic effects induced by these viruses on equine dermal cells, and established the efficacy of this method to evaluate the antiviral effect of aciclovir (ACV) and ganciclovir (GCV). In addition, the RTCA technology has also been found appropriate for the high-throughput screening of small molecules against EHV, allowing the identification of spironolactone as a novel antiviral against EHV.


Subject(s)
Antiviral Agents/pharmacology , Electric Impedance , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/drug effects , High-Throughput Screening Assays/methods , Animals , Cell Line , Cytopathogenic Effect, Viral/drug effects , Herpesviridae Infections/pathology , Herpesviridae Infections/virology , Herpesvirus 1, Equid/classification , Herpesvirus 3, Equid/drug effects , Herpesvirus 4, Equid/drug effects , Horses , Spironolactone/pharmacology
9.
Vet Microbiol ; 183: 110-8, 2016 Feb 01.
Article in English | MEDLINE | ID: mdl-26790943

ABSTRACT

Equine herpesvirus-1 (EHV-1) infects equine endothelial cells (EECs) lining the small blood vessels in the central nervous system. However, the effect of type I IFN on EHV-1 replication in the EECs is not well studied. Thus, the primary objective of this study was to investigate the effect of type-I IFN on the replication of the neuropathogenic T953 strain of EHV-1 in vitro in EECs. The initial data showed that the EHV-1 was partly resistant to the biological effect of exogenously supplied recombinant equine IFN-α. Subsequent investigation into the mechanism of resistance showed that EHV-1 infection of EECs interfered with the STAT-1 phosphorylation through which type-I IFN exerts its antiviral effect. Immunofluorescence staining showed interference with the translocation of STAT-1 molecules from cytoplasm to nucleus confirming the virus mediated suppression of STAT-1 activation. Downstream of the JAK-STAT signaling, EHV-1 infection inhibited expression of cellular antiviral proteins including IFN-stimulated gene 56 (ISG56) and viperin. Taken together these findings suggest that the neuropathogenic T953 strain of EHV-1 evades the host innate immune response by inhibiting IFN and this may provide some insight into the pathogenesis of EHV-1 infection.


Subject(s)
Herpesviridae Infections/virology , Herpesvirus 1, Equid/drug effects , Horse Diseases/virology , Interferon Type I/pharmacology , Animals , Antiviral Agents/pharmacology , Cells, Cultured , Endothelial Cells/virology , Gene Expression Regulation/drug effects , Herpesviridae Infections/immunology , Herpesviridae Infections/physiopathology , Herpesvirus 1, Equid/immunology , Horse Diseases/immunology , Horse Diseases/physiopathology , Horses , Phosphorylation/drug effects , STAT1 Transcription Factor/metabolism , Signal Transduction/drug effects , Virus Replication/drug effects
10.
Mikrobiol Z ; 77(5): 11-9, 2015.
Article in Ukrainian | MEDLINE | ID: mdl-26638480

ABSTRACT

Factors identified that affect the sensitivity of microorganisms to polyhexamethyleneguanidine (PHMG). Salts of PHMG chloride, valerate, maleate, succinate was to use. Test strains of Esherichia coli, Staphylococcus aureus, Bacillus cereus, Leptospira interrogans, Paenibacillus larvae, Mycobacterium bovis, M. avium, M. fortuitum, Aspergillus niger and some strains of viruses are taken as objects of research. We have determined that the cytoplasm membrane phospholipids is main "target" for the polycation molecules of PHMG. A differential sensitivity of the microorganisms to this drug is primarily determined by relative amount of lipids in membrane and their accessibility. Such trends exist: increase the relative contents of anionic lipids and more negative surface electric potential of membrane, and reduction of the sizes fat acid remainder of lipids bring to increase of microorganism sensitivity. Types of anion salt PHMG just have a certain value. Biocide activity of PHMG chloride is more, than its salts with organic acid. Feasibility of combining PHMG with other biocides in the multicomponent disinfectants studied and analyzed. This combination does not lead to a significant increase in the sensitivity of microorganisms tested in most cases. Most species of pathogenic bacteria can be quickly neutralized by aqueous solutions of PHMG in less than 1% concentrations.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antifungal Agents/pharmacology , Antiviral Agents/pharmacology , Disinfectants/pharmacology , Guanidines/pharmacology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/chemistry , Antifungal Agents/administration & dosage , Antifungal Agents/chemistry , Antiviral Agents/administration & dosage , Antiviral Agents/chemistry , Aspergillus niger/drug effects , Aspergillus niger/growth & development , Aspergillus niger/metabolism , Disinfectants/administration & dosage , Disinfectants/chemistry , Dose-Response Relationship, Drug , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/growth & development , Gram-Negative Bacteria/metabolism , Gram-Positive Bacteria/drug effects , Gram-Positive Bacteria/growth & development , Gram-Positive Bacteria/metabolism , Guanidines/administration & dosage , Guanidines/chemistry , Herpesvirus 1, Equid/drug effects , Herpesvirus 1, Equid/growth & development , Herpesvirus 1, Equid/metabolism , Microbial Sensitivity Tests , Phospholipids/metabolism , Species Specificity
11.
J Vet Med Sci ; 77(11): 1545-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26074409

ABSTRACT

We investigated the influences of various reaction conditions on equine herpesvirus type 1 (EHV-1) disinfection by 5 commercial disinfectants (3 quaternary ammonium compounds [QACs] and 2 chlorine-based disinfectants) and 1 anionic surfactant. QACs at their highest recommended concentrations had no virucidal effect on EHV-1 with a 10-min reaction time at 0°C or a 1-min reaction time at room temperature. Chlorine-based disinfectants achieved EHV-1 disinfection with a 10-min reaction time at -10°C or a 30-sec reaction time at room temperature. In the presence of 5% fetal bovine serum, QACs (except for benzalkonium chloride) showed more stable virucidal effects than did chlorine-based disinfectants. The virucidal effect of the anionic surfactant was almost equivalent to that of the QACs.


Subject(s)
Alkanesulfonic Acids/pharmacology , Disinfectants/pharmacology , Herpesvirus 1, Equid/drug effects , Surface-Active Agents/pharmacology , Alkanesulfonic Acids/chemistry , Animals , Chlorine , Disinfectants/chemistry , Surface-Active Agents/chemistry , Time Factors
12.
Antiviral Res ; 93(2): 234-238, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22178244

ABSTRACT

Equine herpesvirus 1 (EHV1) is a ubiquitous equine alphaherpesvirus that causes respiratory disease, neurological symptoms and abortions. Current vaccines are not fully protective and effective therapeutics are lacking. A-5021 [(1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guanine], previously shown to possess potent anti-herpetic activity against most human herpesviruses, was evaluated for its potential to inhibit EHV1 replication. In equine embryonic lung (EEL) cells, infected with either a non-neurovirulent (97P70) or a neurovirulent (03P37) EHV1 isolate, A-5021 proved to be about 15-fold more potent than acyclovir in inhibiting viral replication. Moreover, in equine nasal mucosal explants, A-5021 (at 8 and 32µM) was able to completely inhibit viral plaque formation whereas acyclovir did not exert an antiviral effect at these concentrations. Our data demonstrate that A-5021 is a potent inhibitor of EHV1 replication and may have potential for the treatment and/or prophylaxis of infections with this virus.


Subject(s)
Antiviral Agents/pharmacology , Guanine/analogs & derivatives , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/drug effects , Horse Diseases/drug therapy , Animals , Cell Line , Drug Evaluation, Preclinical , Guanine/pharmacology , Herpesviridae Infections/drug therapy , Herpesviridae Infections/virology , Herpesvirus 1, Equid/physiology , Horse Diseases/virology , Horses , In Vitro Techniques , Nasal Mucosa/virology , Virus Replication/drug effects
13.
Res Vet Sci ; 91(3): e158-62, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21159355

ABSTRACT

The antiviral activity of quercetin, morin and trans-cinnamic acid was evaluated in vitro against equid herpesvirus 1 (EHV-1) by determining the virucidal activity and using the time of addition assay to test inhibition of the viral replication cycle. The cytotoxicity of each substance was assessed using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. Quercetin showed virucidal action and inhibition of the viral replication cycle at 0 and 1h. Morin showed potential virucidal and viral replication cycle inhibition at 0 h. Trans-cinnamic acid did not show virucidal activity but inhibited the viral replication cycle at -1 and 0 h. This study demonstrates the potential of these compounds as future antiviral candidates in relation to viruses of importance in veterinary medicine.


Subject(s)
Antiviral Agents/pharmacology , Cinnamates/pharmacology , Flavonoids/pharmacology , Herpesvirus 1, Equid/drug effects , Quercetin/pharmacology , Animals , Chlorocebus aethiops , Vero Cells
14.
J Vet Med Sci ; 72(3): 357-61, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19959884

ABSTRACT

We investigated the pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses. Following an oral dose of famciclovir at 20 mg/kg, maximum plasma concentrations of penciclovir occurred between 0.75 and 1.5 hr (mean 0.94 + or - 0.38 hr) after dosing and were in the range 2.22 to 3.56 microg/ml (mean 2.87 + or - 0.61 microg/ml). The concentrations of penciclovir declined in a biphasic manner after the peak concentration was attained. The mean half-life of the rapid elimination phase was 1.73 + or - 0.34 hr whereas that of the slow elimination phase was 34.34 + or - 13.93 hr. These pharmacokinetic profiles observed were similar to those of another antiherpesvirus drug, acyclovir, previously reported in horses following oral dosing of its prodrug valacyclovir.


Subject(s)
2-Aminopurine/analogs & derivatives , Acyclovir/analogs & derivatives , 2-Aminopurine/administration & dosage , 2-Aminopurine/blood , 2-Aminopurine/pharmacokinetics , Acyclovir/blood , Acyclovir/pharmacokinetics , Administration, Oral , Animals , Antiviral Agents/blood , Antiviral Agents/pharmacokinetics , Area Under Curve , Famciclovir , Guanine , Half-Life , Herpesviridae Infections/drug therapy , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/drug effects , Horse Diseases/drug therapy , Horse Diseases/virology , Horses
15.
Vet Immunol Immunopathol ; 135(1-2): 93-99, 2010 May 15.
Article in English | MEDLINE | ID: mdl-20004981

ABSTRACT

Recombinant equine interferon-gamma (reIFN-gamma) was prepared using a baculovirus expression system and its antiviral activity was investigated using several equine viruses. The reIFN-gamma suppressed the replication of all equine viruses used in the present experiment in horse cell cultures, but did not affect the growth of host cells at concentrations of less than 1000 u/ml. A strong antiviral effect was observed, especially against RNA viruses. Equine picornavirus, equine rhinovirus and equine arteritis virus could not be propagated at all in 100 u/ml reIFN-gamma when 100 TCID(50) of infective viruses was inoculated to cultivated horse cells. DNA viruses, equine herpesvirus types 1, 2, 3 and 4 and equine adenovirus, were less sensitive to reIFN-gamma but their growth became less than 1/100 in the cells treated with 100 u/ml reIFN-gamma compared to untreated cells. The antiviral effects were decreased in the cells of heterologous species and more than 1000 u/ml reIFN-gamma was required to induce an antiviral effect.


Subject(s)
Adenoviridae/drug effects , Alphavirus/drug effects , Antiviral Agents/pharmacology , Aphthovirus/drug effects , Equartevirus/drug effects , Herpesvirus 1, Equid/drug effects , Herpesvirus 3, Equid/drug effects , Herpesvirus 4, Equid/drug effects , Interferon-gamma/pharmacology , Picornaviridae/drug effects , Rhadinovirus/drug effects , Animals , Antiviral Agents/adverse effects , Cells, Cultured , Dose-Response Relationship, Drug , Horse Diseases/drug therapy , Horse Diseases/virology , Horses/virology , Interferon-gamma/adverse effects , Recombinant Proteins , Virus Replication/drug effects
16.
J Vet Pharmacol Ther ; 32(3): 207-12, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19646083

ABSTRACT

The aim of the current study was to investigate whether multiple oral dosing of valacyclovir could result in plasma concentrations exceeding the EC(50)-value of acyclovir against equine herpesvirus 1 (EHV1) during the majority of the treatment period. Additionally, we wanted to determine the concentration of acyclovir in nasal mucus and cerebrospinal fluid (CSF). Valacyclovir was administered to four horses and two ponies, three times daily, at a dosage of 40 mg/kg, for four consecutive days. Blood was collected prior to each administration and 1 h after dosing. Nasal mucus samples and CSF were collected once during treatment; 1 h after the last administration. This dosage regimen resulted in plasma concentrations that were higher than the EC(50)-value of 1.7 microg/mL, i.e. EC(50) of an isolate highly susceptible to acyclovir, for 80% of the treatment period; and higher than the EC(50)-value of 3.0 microg/mL, i.e. EC(50) of an isolate less susceptible to acyclovir, for 60% of the treatment period. Concentration in nasal mucus samples and CSF was 0.36-1.17 microg/mL and 0.11-0.23 microg/mL, respectively. This study illustrates that multiple dosing of valacyclovir may result in a therapeutic benefit as plasma concentrations could be maintained above the EC(50)-value of acyclovir against EHV1 for more than 50% of the treatment period. Acyclovir could be detected in both nasal mucus samples and CSF. However, these concentrations were lower than the EC(50).


Subject(s)
Acyclovir/analogs & derivatives , Acyclovir/blood , Antiviral Agents/administration & dosage , Horses/metabolism , Mucus/metabolism , Valine/analogs & derivatives , Acyclovir/administration & dosage , Acyclovir/cerebrospinal fluid , Acyclovir/pharmacokinetics , Administration, Oral , Animals , Antiviral Agents/blood , Antiviral Agents/cerebrospinal fluid , Antiviral Agents/pharmacokinetics , Area Under Curve , Chromatography, High Pressure Liquid/veterinary , Drug Administration Schedule/veterinary , Female , Herpesviridae Infections/drug therapy , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/drug effects , Horses/blood , Male , Nasal Mucosa/virology , Serum Bactericidal Test/veterinary , Valacyclovir , Valine/administration & dosage , Valine/blood , Valine/cerebrospinal fluid , Valine/pharmacokinetics
17.
Vet Microbiol ; 135(3-4): 214-21, 2009 Mar 30.
Article in English | MEDLINE | ID: mdl-18986780

ABSTRACT

The purpose of the current study was to investigate the therapeutic efficacy of valacyclovir against EHV1 in a controlled study. Eight naïve Shetland ponies were inoculated with 10(6.5) TCID(50) of the neuropathogenic strain 03P37. Four ponies were treated with valacyclovir at a dosage of 40mg/kg bodyweight, 3 times daily, for 5 (n=2) or 7 (n=2) consecutive days, while the other four ponies served as untreated controls. The treatment regimen started 1h before inoculation. Ponies were monitored daily for clinical signs. At 0, 1, 2, 3, 4, 5, 7, 9, 11, 14, 17 and 21 days post inoculation (d pi), a nasopharyngeal mucus sample was taken to determine viral shedding. At the same time points, blood was collected and peripheral blood mononuclear cells (PBMC) were isolated to determine viremia. During the treatment, blood samples were collected 6 times daily, i.e. just before valacyclovir administration and 1h later, to determine the concentration of acyclovir in plasma. Also a nasopharyngeal swab was taken to measure the acyclovir concentration in nasal secretion. No differences could be noticed between valacyclovir-treated and untreated ponies. The clinical signs, the viral shedding and the viremia were similar in both the groups. Plasma acyclovir concentration could be maintained above the EC(50)-value of EHV1 during 50% of the entire treatment period in valacyclovir-treated ponies. Acyclovir could be detected in nasal swabs at concentrations varying from 50% to 100% of the corresponding plasma concentration. Although sufficiently high acyclovir levels could be reached in plasma and nasal mucus, no effect was seen of the treatment with valacyclovir on clinical signs, viral shedding and viremia of EHV1-infected ponies.


Subject(s)
Acyclovir/analogs & derivatives , Antiviral Agents/therapeutic use , Herpesviridae Infections/drug therapy , Herpesviridae Infections/veterinary , Horse Diseases/drug therapy , Horse Diseases/virology , Valine/analogs & derivatives , Acyclovir/blood , Acyclovir/therapeutic use , Animals , Antiviral Agents/blood , Body Temperature/drug effects , Dose-Response Relationship, Drug , Fever/drug therapy , Fever/veterinary , Herpesvirus 1, Equid/drug effects , Herpesvirus 1, Equid/isolation & purification , Horses , Valacyclovir , Valine/blood , Valine/therapeutic use , Virus Shedding/drug effects
18.
Vet Microbiol ; 122(1-2): 43-51, 2007 May 16.
Article in English | MEDLINE | ID: mdl-17276631

ABSTRACT

Equine herpesvirus 1 (EHV-1) is an important equine pathogen that causes respiratory disease, abortion, neonatal death and paralysis. Although vaccines are available, they are not fully protective and outbreaks of disease may occur in vaccinated herds. Therefore, there is an urgent need for effective antiviral treatment. For three abortigenic (94P247, 97P70 and 99P96) and three neuropathogenic isolates (97P82, 99P136 and 03P37), the effect of acyclovir, ganciclovir, cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) and foscarnet on plaque number was studied. Additionally, for isolate 97P70, the effect on plaque size was investigated. Ganciclovir was most potent in reducing plaque number, followed by PMEDAP and acyclovir. Adefovir and cidofovir were less effective and foscarnet was the least effective compound. There were no differences detected for acyclovir, ganciclovir, adefovir and PMEDAP between the abortigenic and neuropathogenic isolates. One abortigenic isolate (99P96) was more susceptible to cidofovir and two neuropathogenic isolates (99P136 and 03P37) were less susceptible to foscarnet. For isolate 97P70, all compounds resulted in a significant reduction of plaque size. The most remarkable effect was observed for cidofovir. It was 40-fold more effective in reducing plaque size than in reducing plaque number. In conclusion, ganciclovir was the most potent compound and therefore, may be a valuable candidate for the treatment of EHV-1 infections in horses. The antiviral effect of foscarnet on plaque number was highly dependent on the viral isolate tested. Therefore, it is no valuable antiviral for the treatment of herpesvirus-infections. Cidofovir, although less effective in reducing plaque number, had a strong effect on plaque size.


Subject(s)
Acyclovir/pharmacology , Adenine/analogs & derivatives , Cytosine/analogs & derivatives , Foscarnet/pharmacology , Ganciclovir/pharmacology , Herpesvirus 1, Equid/drug effects , Organophosphonates/pharmacology , Adenine/pharmacology , Animals , Antiviral Agents/pharmacology , Cell Survival/drug effects , Cells, Cultured , Cidofovir , Cytosine/pharmacology , Dose-Response Relationship, Drug , Drug Resistance, Viral , Epithelial Cells/drug effects , Horses , Lung/cytology
19.
J Gen Virol ; 84(Pt 2): 293-300, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12560560

ABSTRACT

There is good evidence that cytotoxic T lymphocytes play an important role in the clearance of equine herpesvirus-1 (EHV1) in horses. We have demonstrated that, in common with other alphaherpesviruses, EHV1 infection can lead to dramatic down-regulation of MHC class I expression at the cell surface, a common strategy for pathogen evasion of the host immune response. This down-regulation is specific for MHC class I and does not reflect a general shut-off of host-cell protein synthesis. The use of monoclonal antibodies that recognize different MHC class I epitopes has demonstrated that the effect may be allele- or locus-specific. Use of the viral DNA synthesis inhibitor phosphonoacetic acid, which prevents late viral gene expression, showed that the effect is mediated by an immediate-early or early viral gene, and use of the protein translation inhibitor cycloheximide confirmed that an early gene is primarily responsible. The data indicate that EHV1 infection results in enhanced endocytosis of MHC class I from the cell surface; the only other herpesvirus reported to use this mechanism is human herpesvirus-8. Elucidation of the precise mechanisms used by EHV1 in this process and identification of the genes responsible may lead to improved vaccination strategies.


Subject(s)
Down-Regulation , Genes, MHC Class I , Herpesvirus 1, Equid/pathogenicity , Histocompatibility Antigens Class I/metabolism , Immediate-Early Proteins/metabolism , Alleles , Animals , Cell Line , Cycloheximide/pharmacology , Enzyme Inhibitors/pharmacology , Herpesvirus 1, Equid/drug effects , Histocompatibility Antigens Class I/genetics , Immediate-Early Proteins/genetics , Phosphonoacetic Acid/pharmacology , Protein Synthesis Inhibitors/pharmacology
20.
Arch Virol ; 142(9): 1849-56, 1997.
Article in English | MEDLINE | ID: mdl-9672642

ABSTRACT

Heparin extensively inhibited infection of MDBK cells by equine herpesvirus 1 (EHV-1) strains adapted to bovine cells or hamsters, while the reagent merely reduced infectivity of strains passaged only in equine cells. The gC of two strains adapted to non-equine cells seemed to have higher affinity for heparin, although the reagent bound to both the gC and gB of all strains tested. Amino acid substitutions of the gC of the EHV-1 strains adapted to non-equine cells converged on the hydrophilic regions, amino acid residues 92 to 175, resulting in the glycoprotein becoming more cationic. These results indicate that these hydrophilic regions of the gC may be responsible for binding to heparin.


Subject(s)
Heparin/pharmacology , Herpesvirus 1, Equid/drug effects , Mutation , Viral Envelope Proteins/metabolism , Adaptation, Physiological , Amino Acid Substitution , Animals , Binding, Competitive , Cattle , Cell Line , Cricetinae , Genes, Viral , Heparin/metabolism , Herpesvirus 1, Equid/genetics , Herpesvirus 1, Equid/physiology , Horses , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/genetics , Viral Structural Proteins/genetics , Virus Cultivation
SELECTION OF CITATIONS
SEARCH DETAIL
...